Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.73 EUR

-0.57 %

2,190 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-0.57 %
-6.99 %
-25.75 %
-30.52 %
-35.93 %
-46.93 %
-59.20 %
-
-65.81 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
58.29M EUR
Turnover
41.61K EUR
P/E (adj.) (26e)
-6.98
EV/EBIT (adj.) (26e)
-7.21
P/B (26e)
4.31
EV/S (26e)
12.89
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
2026-03-08
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-03-09

Latest extensive report

Released: 2025-04-24

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Aiforia is organizing a webinar to present Aiforia’s new Foundation Engine. "AI model development used to be a marathon of data and time, but we have built a shortcut. Join Aiforia’s CPO and Director of Software Development to discover how Aiforia’s Foundation Engine elevates your...
4/3/2026, 9:51 AM
by Jekkku
18
As I was idly browsing Aiforia’s old news, I suddenly came across this win from 2023. Aiforia receives a contract award to provide AI solutions for 25 NHS hospitals of the PathLAKE Plus consortium in the UK The duration of the individual contracts with the hospitals will be three...
4/7/2026, 1:40 PM
by Jekkku
15
The largest owners apparently disagreed with the board on the method of raising funds. Is it correct that the board needs over 50% of the individual votes among themselves to make a proposal, but in the general meeting, over one-third of the voting power is enough to oppose the decision...
4/3/2026, 7:18 AM
by Vino Pino
11
Joensuun Kauppa ja Kone Oy’s visit was short. It’s no longer on the list.
4/1/2026, 12:42 PM
by TO
11
I noticed this point from the general meeting’s decisions: “The General Meeting decided not to approve the share issue authorization proposed by the board of directors.” What does that practically mean regarding potential financing needs?
4/3/2026, 4:27 AM
by Salvelinus
10
I’m linking the mentioned Kauppalehti discussion thread here, even though I don’t consider it a reliable source: Aiforia | Sivu 21 | Kauppalehden keskustelupalsta I’m not sure how credible it is that a 3% ownership stake can push anything through, especially with the current possibility...
4/3/2026, 7:06 AM
by NukkeNukuttaja
8
Inside Precision Medicine – 7 Apr 26 The Digital Path to AI in Cancer Care The ability of AI to interpret and annotate tumor sample slides that have been digitized is taking center stage. This news also prominently features many partners associated with Aiforia, as well as competitors...
4/9/2026, 7:48 AM
by Salvelinus
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.